Review
Oncology
Abigail L. Mende, Jessica D. Schulte, Hideho Okada, Jennifer L. Clarke
Summary: This review discusses the development of novel immunotherapies for glioblastoma, including recent clinical trials and technologies to overcome challenges specific to the central nervous system. The success of immunotherapy in other solid cancers has prompted exploration of its application in glioblastoma, highlighting the need for multimodal treatment regimens.
CURRENT ONCOLOGY REPORTS
(2021)
Review
Oncology
Meagan Mandabach Olivet, Michael C. Brown, Zachary J. Reitman, David M. Ashley, Gerald A. Grant, Yuanfan Yang, James M. Markert
Summary: There are limited treatment options for recurrent glioblastoma (rGBM), but immunotherapy offers new hope. This literature review summarizes recent clinical studies on immunotherapy for rGBM, including immune checkpoint blockade, oncolytic virotherapy, CAR T-cell therapy, cancer vaccine, and antibody-conjugated toxin. The review provides an overview of treatment advances, limitations, ongoing opportunities, and correlates to survival, aiming to support clinical decision-making and guide future research for this devastating disease.
Article
Medicine, General & Internal
Shuguang Zuo, Min Wei, Bohao He, Anxian Chen, Shiqun Wang, Lingkai Kong, Yenan Zhang, Gang Meng, Tiancheng Xu, Jingyi Wu, Fuming Yang, Hailin Zhang, Shibing Wang, Ciliang Guo, Junhua Wu, Jie Dong, Jiwu Wei
Summary: The study demonstrates that VV-alpha-TIGIT exhibits effective anti-tumor efficacy in various tumor models, particularly achieving approximately 70% complete tumor regression in an ascites tumor model. Treatment with VV-alpha-TIGIT also significantly increases the recruitment and activation of T cells in TME.
Review
Oncology
Mark Dapash, Brandyn Castro, David Hou, Catalina Lee-Chang
Summary: This review discusses various immunotherapeutic strategies currently being investigated in the treatment of glioblastoma, including checkpoint inhibitors, vaccination strategies, and CAR T-cell therapy. However, due to the low immunogenicity of the tumor, treatment outcomes remain suboptimal.
Review
Biochemistry & Molecular Biology
Ugur Sener, Michael W. Ruff, Jian L. Campian
Summary: Glioblastoma is the most common malignant brain tumor, and immunotherapy approaches for its treatment are still challenging, although multiple studies are underway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Microbiology
Yaqi Zhao, Zheming Liu, Lan Li, Jie Wu, Huibo Zhang, Haohan Zhang, Tianyu Lei, Bin Xu
Summary: Immunotherapy, particularly utilizing oncolytic viruses like adenovirus, has become a forefront approach in modern oncologic treatment. Genetic engineering allows for the design of oncolytic adenoviruses with better tumor targeting and efficacy, and strategies like adding tumor-specific promoters and immunostimulatory transgenes have shown promise in cancer immunotherapy. Combining oncolytic adenoviruses with immune checkpoint inhibitors has demonstrated increased clinical benefit in ongoing trials, although challenges such as antiviral immune response and tumor microenvironment obstruction need to be addressed.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Oncology
Jianhan Huang, Meijun Zheng, Zongliang Zhang, Xin Tang, Yaxing Chen, Aijun Peng, Xingchen Peng, Aiping Tong, Liangxue Zhou
Summary: The combination of oncolytic adenovirus loaded with interleukin-7 and B7H3-targeted CAR-T showed enhanced T cell proliferation and reduced apoptosis, leading to prolonged survival and reduced tumor burden in glioblastoma-bearing mice. The study indicated that the oncolytic adenovirus could improve the therapeutic efficacy of CAR-T by providing activating signals for tumor-infiltrating T cells, laying the foundation for future clinical trials in glioblastoma treatment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Immunology
Sun Il Choi, Jinlong Yin
Summary: Glioblastoma (GBM) is the most common malignant brain tumor, and alternative tumor-specific therapies are urgently needed. Chimeric antigen receptor (CAR) T cell therapy shows promise for hematological malignancies, but its effectiveness for solid tumors, especially GBM, needs improvement. This review discusses strategies for enhancing CAR T cell effectiveness in GBM treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Wesam Kooti, Hadi Esmaeili Gouvarchin Ghaleh, Mahdieh Farzanehpour, Ruhollah Dorostkar, Bahman Jalali Kondori, Masoumeh Bolandian
Summary: Recent studies have shown that oncolytic viruses have high potential in cancer treatment by achieving targeted treatment effects through selective cell death and inducing specific antitumor immunity. Understanding the mechanisms of action of oncolytic viruses can be beneficial in cancer therapy.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Shaoming Zhu, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li, Chong-xian Pan
Summary: This review discusses the relationship between cancer immune response and resistance mechanisms to immunotherapy, as well as provides a comprehensive overview of the latest clinical status and FDA-approved combination therapies. It also covers therapies targeting cytokines, immunotherapy, virotherapy, innate immune modifiers, and cancer vaccines, as well as insights from the 2020 China Immuno-Oncology Workshop.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Oncology
Laura Evgin, Richard G. Vile
Summary: Chimeric Antigen Receptor (CAR) modified T cell therapy has significantly advanced the treatment of B cell malignancies, but faces challenges when applied to solid tumors. Combining oncolytic viruses (OVs) and adoptive T cell therapy (ACT) shows potential, but careful consideration is needed to maximize efficacy and minimize interference. While OVs and CAR T cells each offer unique benefits, not all virus-induced effects may be favorable for CAR T therapy.
Review
Chemistry, Multidisciplinary
Yen N. Diep, Tae Jin Kim, Hansang Cho, Luke P. Lee
Summary: This article discusses the applications of medical nanoparticles in enhancing cancer immunotherapy, including delivering vaccines to lymph nodes, improving therapeutic effects and overcoming drug resistance in antibody therapy, and enhancing the efficacy of CAR T cell therapy.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Oncology
Chaoqun Wang, Yuntao Li, Lijuan Gu, Ran Chen, Hua Zhu, Xu Zhang, Yonggang Zhang, Shi Feng, Sheng Qiu, Zhihong Jian, Xiaoxing Xiong
Summary: This article briefly introduces the application of chimeric antigen receptor T cell therapy in the treatment of glioblastoma. Glioblastoma is the most prevalent cerebral cancer in adults without proven therapy. Chimeric antigen receptor T cell therapy has demonstrated good clinical success in hematologic cancers, and its application to solid tumors is being studied.
Article
Cell Biology
Chen Chen, Weiqiang Jing, Yu Chen, Ganyu Wang, Mohnad Abdalla, Lin Gao, Maosen Han, Chongdeng Shi, Anning Li, Peng Sun, Xin Jiang, Zhenmei Yang, Shengchang Zhang, Jing Zhang, Chunwei Tang, Ying Liu, Rui Zhang, Fengbo Xu, Baixiang Dong, Xueen Li, Minglu Liu, Bangming Qiang, Yanhua Sun, Xia Wei, Jun Li, Quanyin Hu, Xinyi Jiang
Summary: Researchers have developed a cavity-injectable nanoporter-hydrogel superstructure to prevent relapse of glioblastoma multiforme (GBM). This superstructure introduces glioma stem cell-specific chimeric antigen receptor (CAR) genes into macrophages/microglia, stimulating an antitumor immune response and preventing postoperative relapse.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Review
Oncology
Andrew S. Luksik, Eli Yazigi, Pavan Shah, Christopher M. Jackson
Summary: Glioblastoma is a common and deadly brain cancer, and current treatments have limited effectiveness. Immunotherapy, particularly CAR T therapy, has shown promise in preclinical experiments but has not yet been proven beneficial in clinical studies.